ZIM
CSTL icon

Zacks Investment Management’s Castle Biosciences CSTL Stock Holding History

Zacks Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-46,030
Closed -$1.05M – 656
2023
Q1 		$1.05M Buy
46,030
+3,541
+8% +$86.5K 0.01% 356
2022
Q4 		$1M Buy
+42,489
New +$985K 0.01% 360
2021
Q1 		– Sell
-14,673
Closed -$985K – 518
2020
Q4 		$985K Buy
+14,673
New +$795K 0.02% 350

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zacks Investment Management's CSTL Position: Q2 2023 in Review

Zacks Investment Management sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 46,030 shares — an estimated $1.05M sold.

Zacks Investment Management first reported a position in CSTL in Q4 2020 and held it in 3 quarters. The position peaked at $1.05M in Q1 2023. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Zacks Investment Management reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Zacks Investment Management sold 46,030 Castle Biosciences shares in Q2 2023, an estimated $1.05M.
  • Zacks Investment Management first reported a position in Castle Biosciences in Q4 2020 and held it in 3 quarters.
  • Zacks Investment Management's Castle Biosciences position peaked at $1.05M in Q1 2023.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Zacks Investment Management's 13F filing for Q2 2023, filed 15 Aug 2023.